폐의 편평세포암에 대한 이해와 표적치료 전망에 대한 최신 지견
- 최초 등록일
- 2013.03.24
- 최종 저작일
- 2013.03
- 12페이지/
MS 파워포인트
- 가격 2,000원
소개글
저널클럽에서 발표했던 자료입니다.
2012년 lancet oncology의 논문으로, 폐의 squamous cell carcinoma에서 발견되는 mutation과 관련하여
targeted therapy의 전망을 알아본 리뷰 논문입니다.
가장 최근까지의 결과를 담고 있으므로
앞으로 연구를 계획하고 계신 의학, 약학 관련 선생님들께 모두 도움이 될 것 같습니다.
목차
1. Introduction
2. Pathology of SqCC
3. Histology-driven management
4. Carcinogenesis and biological heterogeneity
5. Controversies and known targets
6. Emerging targetable driver events
7. Conclusion
본문내용
Introduction
Molecular mechanisms of NSCLC are reshaping the landscape of clinical care
Adenocarcinoma : Driver events identification
Targeted therapies (erlotinib, gefitinib, crizotinib) in 30%
Squamous-cell carcinoma : New genetic changes are uncovered in substantial proportion
Promising targeted therapies can be revealed
Squamous-cell carcinoma
20 30% of NSCLCs / Associated most strongly with cigarette smoking
Decreased since 1960s
improved diagnostic approaches
changes in cigarette design and composition
change in cigarette smoke inhalation patterns
Symptomatic with central tumors in the bronchi
Cough, Shortness of breath, Fever (Atelectasis & Post-obstructive pneumonia), Hemoptysis
<중 략>
A distinct mutant form of type III EGFR deletion mutant (EGFR vIII)
In a few SqCCs : 5 8% / HG gliomas, SqCC in head and neck
Not thought to be sensitive to reversible TKI therapy
The PI3K pathway (PI3K/PTEN/AKT/mTOR)
Signal transduction pathway central to Cell survival, Metabolism, Motility, and Angiogenesis
More common abnormality in SqCC
PIK3CA
mutation : 3.6 6.5%
amplification : 43% by FISH / 42% by PCR
AKT1
참고 자료
Lancet Oncol. 2012 Oct;13(10):e418-26. doi: 10.1016/S1470-2045(12)70291-7.
Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy.
Drilon A. et al.
